Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03417479 · ClinicalTrials.gov registry record
Gabapentin Premedication for ACL Reconstruction: RCT
A clinical trial, sponsored by Children's Healthcare of Atlanta.
- Completed
- Registry status
- 57
- Enrollment target
NCT03417479: Completed study, sponsored by Children's Healthcare of Atlanta.
NCT03417479 is a clinical trial that has completed, run by Children's Healthcare of Atlanta. The registered enrollment target is 57 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03417479 has completed, sponsored by Children's Healthcare of Atlanta.
- COMPLETED
- Registry status
- 57 participants
- Enrollment target
Study Summary
This double blind randomized control trial will enroll 100 participants ages 12-18 years, undergoing ACL repair. Participants receive gabapentin or placebo preoperatively. Outcome measurements of self-reported pain score using scale of 1 to 10 with 10 being the worse obtained from the EMR and participants interviews with a phone nurse for five days postoperatively to determine severity of pain as well as use of opioids.
Primary Outcome
To determine whether one 15mg/kg (up to 600 mg) dose of gabapentin preoperatively reduces pain after ACL surgery over the first 5 days of the postoperative period
Interventions
- OTHER Gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2015-10-09 |
| Est. Completion | 2018-10-23 |
What the finished NCT03417479 record still lists
NCT03417479 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 57 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Gabapentin is the first listed.
NCT03417479 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03417479 about?
NCT03417479 is a clinical study titled "Gabapentin Premedication for ACL Reconstruction: RCT". This double blind randomized control trial will enroll 100 participants ages 12-18 years, undergoing ACL repair. Participants receive gabapentin or placebo preoperatively. Outcome measurements of self-reported pain score using scale of 1 to 10 with 10 being the worse obtained from the EMR and partic...
What is the current status of trial NCT03417479?
This trial is currently completed. The enrollment target is 57 participants. The study started on 2015-10-09. Estimated completion is 2018-10-23.
What interventions are being tested in trial NCT03417479?
The interventions under investigation include: Gabapentin (OTHER).
Who is sponsoring clinical trial NCT03417479?
This trial is sponsored by Children's Healthcare of Atlanta, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI